Research programme: retinal disease therapies - RIKEN/Shin Nippon Biomedical Laboratories

Drug Profile

Research programme: retinal disease therapies - RIKEN/Shin Nippon Biomedical Laboratories

Alternative Names: Cell therapies for ophthalmic diseases - Shin Nippon Biomedical Laboratories (SNBL)/RIKEN; Induced pluripotent stem (iPS) cells for eye disorders - Shin Nippon Biomedical Laboratories; iPS cell-derived RPE cell transplantation for Age-related macular degeneration - Healios/Shin Nippon Biomedical Laboratories; iPSC-derived RPE sheet - RIKEN/Healios; Retinal pigment epithelial (RPE) cells for AMD - Healios/RIKEN

Latest Information Update: 09 Dec 2013

Price : $50

At a glance

  • Originator RIKEN
  • Developer Healios; RIKEN; Shin Nippon Biomedical Laboratories
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration; Eye disorders

Most Recent Events

  • 02 Dec 2013 Retina Institute Japan is now called Healios
  • 17 Jul 2013 Shin Nippon Biomedical Laboratories (SNBL) executes Letter of Intent Agreement on joint research with Retina Institute Japan for development and non-clinical research of iPS cell-derived RPE cell transplantation for Age-related macular degeneration
  • 15 Jul 2013 Shin Nippon Biomedical Laboratories (SNBL) executes a 3-year Joint Research Agreement with RIKEN related to development of stem cell therapies for ophthamic disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top